

### **ORAL PRESENTATION**

**Open Access** 

# Olive leaf extract improves insulin sensitivity in overweight middle aged males; a randomized, double-blinded, placebo controlled, crossover trial

Martin de Bock<sup>\*</sup>, Jose Derraik, Christine Brennan, Eric Thorstensen, Wayne Cutfield<sup>†</sup>

From 7th APPES Biennial Scientific Meeting Nusa Dua, Bali. 14-17 November 2012

#### **Aim**

To investigate the impact of supplement olive leaf extract on insulin sensitivity in overweight middle aged males.

#### Method

We conducted a randomized, double-blinded, placebo controlled, crossover trial on an overweight middle aged male population at risk of developing the metabolic syndrome comparing olive leaf extract containing 51 mg oleuropein and 9.7 mg hydroxytyrosol to placebo. We measured insulin sensitivity (Matsuda method), pancreatic b-cell responsiveness (oral disposition index), lipid profile, ambulatory blood pressure, carotid intimal media thickness, body composition (DEXA) basal metabolic rate, hand-grip strength, wellness questionnaire, inflammatory cytokines, antioxidant potential all measured at baseline and end of both interventions.

#### **Results**

38 participants were suitable for analysis. Even after controlling for total calorie intake fibre intake, physical activity, age, and percentage body fat (DEXA), insulin sensitivity was significant improved on treatment Vs placebo (19% p= <0.05), as well as the oral disposition index as a marker of pancreatic b-cell responsiveness (30% p=, 0.05). The cytokine profile was consistent with improved insulin sensitivity: acutely raised IL-6, IGFBP1 and IGFBP2. No other clinical outcomes were influenced.

#### **Conclusion**

Olive leaf extract improves insulin sensitivity in overweight middle aged males. This is applicable to an overweight adolescent population.

Published: 3 October 2013

doi:10.1186/1687-9856-2013-S1-O34

Cite this article as: de Bock *et al.*: Olive leaf extract improves insulin sensitivity in overweight middle aged males; a randomized, double-blinded, placebo controlled, crossover trial. *International Journal of Pediatric Endocrinology* 2013 **2013**(Suppl 1):O34.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



<sup>†</sup> Contributed equally Liggins Institute, University of Auckland, Auckland, New Zealand

